克拉德里宾片作为高级复发性复发性多发性硬化症的治疗方法:一个为期4年的随访真实世界,多中心,回顾性,队列研究
Aleksandra Pogoda-Wesołowska1, Adam Stępień1, Marcin Wnuk2
1Department of Neurology, Military Institute of Medicine, Warsaw, Poland.
Frontiers in neurology
|July 21, 2025
概括
克拉迪宾片 (CladT) 有效地减少了波兰复发性复发性多发性硬化症 (RRMS) 患者的复发和MRI活动,即使疾病已晚期. 这项研究证实了CladTT的存在.
科学领域:
- 神经学 神经学
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
背景情况:
- 克拉迪宾片 (CladT) 是一种推的高效疾病修饰疗法,用于复发性复发性多发性硬化症 (RRMS).
- 目前的建议往往针对早期RRMS,对更晚期疾病患者的长期疗效的数据较少.
- 在现实世界波兰RRMS群体中评估CladT,并可能推迟开始治疗至关重要.
研究的目的:
- 评估克拉迪宾片 (CladT) 在波兰复发性复发性多发性硬化症 (RRMS) 患者队列中的长期疗效和安全性.
- 为了评估RRMS患者的治疗结果,RRMS患者患有更晚期的疾病和多种先前治疗的病史.
- 分析年度复发率 (ARR),MRI活动,扩展残疾状态量表 (EDSS) 评分和没有疾病活动证据 (NEDA-3) 状态.
主要方法:
- 在2019年12月至2023年11月期间,对230名RRMS患者开始CladT的回顾性观察研究.
- 收集的数据包括先前的治疗,ARR,MRI活动,EDSS,NEDA-3状态,淋巴细胞计数和安全结果.
- 研究人员分析了治疗开始后长达4年的随访数据.
主要成果:
- 显著减少ARR从1.42在基线到0.22-0.36在1-3年. 高比例的无复发患者 (75.4-82%) 在1-3年.
- 活跃的MRI病变明显减少,从基线时的90.4%降至4年后的8.3%. 在73.7-88.9%的患者中观察到稳定或改善的EDSS.
- 在1至4年间,有40.4-71.4%的患者获得了NEDA-3状态. 在16.7% (1年至2年) 和6.3% (3年) 报告的不良事件.
结论:
- 克拉迪片 (CladT) 显示出显著的长期疗效,减少了波兰RRMS患者的疾病活性,包括那些晚期疾病患者.
- 这种治疗在具有高疾病活性和延迟开始治疗的群体中是有效的.
- 在这个现实世界的RRMS队列中,CladT表现出有利的安全概况.
相关概念视频
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
236
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
236
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
203
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
203
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
271
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
271
Clinical Trials: Overview
3.4K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
3.4K
Clinical Trials
8.5K
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
There are four phases in a clinical trial. A phase one...
8.5K
Drug Administration and Therapy Phases: Overview
761
Drugs, the chemical agents used in diagnosing, treating, or preventing diseases, undergo a four-phase process of development: pharmaceutic, pharmacokinetics, pharmacodynamics, and therapeutic.
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
761


